Lite Strategy (LITS) Interest & Investment Income (2010 - 2026)
Lite Strategy (LITS) posted quarterly Interest & Investment Income of $54000.0 for Q1 2026, down 73.27% year-over-year from $202000.0 in Q1 2025, and down 10.0% quarter-over-quarter from $60000.0 in Q4 2025.
Lite Strategy (LITS) Interest & Investment Income (2010 - 2026) Analysis & Trends
Lite Strategy's Interest & Investment Income history runs 17 years deep, the most recent figure standing at $54000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 73.27% year-over-year to $54000.0; the TTM figure through Mar 2026 stood at $404000.0 (down 72.02% YoY), while the FY2025 annual figure was $1.0 million, down 68.69% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $54000.0, down from $60000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $1.1 million in Q3 2023, with the low at $54000.0 in Q1 2026.
- The 5-year median for Interest & Investment Income is $355000.0 (2024), against an average of $478117.6.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income surged 7581.82% in 2022, then plunged 78.49% in 2025.
- Lite Strategy's Interest & Investment Income stood at $845000.0 in 2022, then advanced by 2.84% to $869000.0 in 2023, then slumped by 67.89% to $279000.0 in 2024, then slumped by 78.49% to $60000.0 in 2025, then declined by 10.0% to $54000.0 in 2026.
- Business Quant data shows LITS's Interest & Investment Income at $54000.0 in Q1 2026, $60000.0 in Q4 2025, and $100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | 54,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54,000.00 |
| Dec 31, 2025 | 60,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 190,000.00 |
| Mar 31, 2025 | 202,000.00 |
| Dec 31, 2024 | 279,000.00 |
| Sep 30, 2024 | 355,000.00 |
| Jun 30, 2024 | 608,000.00 |
| Mar 31, 2024 | 706,000.00 |
| Dec 31, 2023 | 869,000.00 |
| Sep 30, 2023 | 1.09 Mn |
| Jun 30, 2023 | 1.06 Mn |
| Mar 31, 2023 | 957,000.00 |
| Dec 31, 2022 | 845,000.00 |
| Sep 30, 2022 | 480,000.00 |
| Jun 30, 2022 | 206,000.00 |
| Mar 31, 2022 | 60,000.00 |
| Dec 31, 2021 | 11,000.00 |
| Sep 30, 2021 | 8,000.00 |
| Jun 30, 2021 | 13,000.00 |